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In this issue ofCell, Gabut and colleagues (2011) identify a new splice variant of FOXP1 that directly
regulates the expression of pluripotency genes. It endows human embryonic stem cells with their
pluripotent nature and is required for the reprogramming of somatic cells to induced pluripotent
stem cells.The past few years have seen remarkable
progress inourunderstandingof themech-
anistic basis of pluripotency, including the
identification of key factors required for
maintaining the pluripotent state of human
embryonic stem cells (ESCs) (Chen et al.,
2008; Kim et al., 2008; Silva et al., 2009).
Moreover, one of the great breakthroughs
of this decade was the discovery that
a only few critical transcriptions factors,
such as the combination of Oct4, Sox2,
Klf4, and c-Myc, are sufficient to repro-
gram somatic cells into induced pluripo-
tent stem (iPS) cells (Takahashi et al.,
2007). These factors appear to activate
a transcriptional network that endowscells
with pluripotency (Samavarchi-Tehrani
et al., 2010), but gene expression can be
regulated by numerous processes other
than transcription, including chromatin
modifications, RNA stability, and pre-
RNA splicing. How these processes
contribute topluripotency has been largely
understudied in human ESCs. Now in this
issue of Cell, Gabut et al. (2011) break
this field wide open by identifying an alter-native splicing ‘‘switch’’ at the top of the
pluripotency transcriptional network.
Alternative splicing—the process by
which exons can be joined together in
different patterns such that a single gene
can give rise to multiple transcripts—is
known to regulatekeydevelopmental deci-
sions in a number of systems (Nilsen and
Graveley, 2010). Perhaps the best known
example is the sex-determination pathway
in Drosophila (Salz, 2011). This pathway
consists of five genes encoding pre-
mRNAs that are spliced in a sex-specific
manner (Figure 1A). The genes are orga-
nized in a hierarchy in which the splicing
of an upstream gene regulates that of
downstream genes. The genes at the
bottom of this hierarchy, dsx (doublesex)
and fru (fruitless), encode transcription
factors, and the male-specific and
female-specific protein variants of each
factor regulatedistinct setsof target genes.
Thus, these regulated splicing events act
in a switch-like manner to specify nearly
all aspects of sex determination and court-
ship behavior.To explore the role of alternative
splicing in human ESC pluripotency, Ga-
but et al. use microarrays that can detect
different splicing variants. These experi-
ments reveal numerous splicing events
that change as human ESCs differentiate
into neural precursor cells, including one
in the FOXP1 gene. This event involves
a previously unannotated exon that is
included in human ESCs but skipped in
differentiated cells (Figure 1B). Strikingly,
the exon’s sequence and its stem cell
specificity is conserved in mouse, sug-
gesting that it might play a significant
role in stem cell biology.
FOXP1 encodes a member of the fork-
head family of transcription factors, which
recognize particular DNA sequences
through a ‘‘forkhead domain.’’ FOXP1 is
an essential gene that is broadly ex-
pressed and required for the establish-
ment of specific cell types. Fusions of
FOXP1 with other genes or loss of FOXP1
function are associated with many dif-
ferent types of cancer (Wang et al., 2004;
Dasen et al., 2008). Intriguingly, the
Figure 1. Alternative Splicing Regulatory Switches
(A) A cascade of alternative splicing regulatory switches control sex determination in Drosophila; Sxl (Sex lethal), tra (transfer),msl-2 (male-specific lethal-2), dsx
(doublesex), and fru (fruitless) genes are all differentially spliced inmales and females. Sxl encodes a female-specific RNA-binding protein that autoregulates itself
and represses the male-specific isoforms of tra and msl-2. The female-specific isoform of tra encodes a female-specific RNA-binding protein that activates
expression of the female-specific isoforms of both dsx and fru. These isoforms encode female-specific transcription factors that activate expression of genes
specifying female physical traits and sexual behavior.
(B) An alternative splicing regulatory switch in FOXP1 regulates pluripotency and reprogramming (Gabut et al., 2011). FOXP1 contains two exons, 18 and 18b,
which are spliced in a mutually exclusive manner. In embryonic stem cells (ESCs), exon 18b is included. This results in the production of FOXP1-ES, which binds
to and activates pluripotency genes while simultaneously repressing differentiation genes. In differentiated cells, only exon 18 is included, resulting in the
production of FOXP1, which activates the expression of differentiation genes.ES-specific exon is locatedwithin the fork-
head domain, suggesting that the FOXP1
splice variants may encode proteins with
distinct DNA-binding specificities. To ex-
amine this possibility, Gabut and col-
leagues determine the DNA-binding spec-
ificity of both the traditional FOXP1 and
the ES-specific FOXP1 (FOXP1-ES) with
microarrays that contain oligonucleotides
with all possible 8-mers. Whereas FOXP1
preferentially recognizes the sequence
GTAAACA, FOXP1-ES preferentially binds
to AATAAACA and CGATACAA. These
results suggest that alternative splicing of
FOXP1 could regulate the activation of
distinct transcriptional programs.
Next Gabut and colleagues use two
complementary approaches to determine
whether FOXP1 and FOXP1-ES control
different sets of genes. First, they deplete
either FOXP1 or FOXP1-ES by RNA inter-
ference (RNAi) and then sequence the
resulting transcriptome. This allows them
to identify genes that increase or decrease
expression upon disruption of a specific
FOXP1 isoform. Additionally, the authors
use chromatin immunoprecipitation ex-
periments to identify where FOXP1 and
FOXP1-ES bind in the genome. Theresults of these experiments are striking.
FOXP1-ES, but not FOXP1, enhances
expression of many pluripotency genes,
including OCT4, NR5A2, and NANOG,
by directly binding to their promoters.
Simultaneously, FOXP1-ES represses
the expression of genes that control
differentiation.
These intriguing observations prompt
the authors to investigate the role and re-
quirement for FOXP1-ES in stem cell plu-
ripotency and reprogramming. Increasing
the expression of FOXP1-ES, but not
FOXP1, prevents differentiation of mouse
ESCs under conditions that promote
efficient differentiation. Conversely, de-
pleting FOXP1-ES, but not FOXP1,
inhibits reprogramming of mouse embyr-
onic fibroblasts via the activation of
Oct4, Klf4, c-Myc, and Sox2.
The article by Gabut and colleagues is
a landmark study that shifts the paradigm
for mechanisms regulating embryonic
stem cell pluripotency and reprogram-
ming in mammals. Instead of a transcrip-
tional network being at the top of the hier-
archy, an alternative splicing switch can
now be placed upstream of this network,
as FOXP1-ES activates expression of plu-Cell 147, Sripotency genes and represses expres-
sion of differentiation genes. Despite
changing our understanding of the regula-
tory network controlling pluripotency and
reprogramming, this work also raises
many questions to be addressed in future
studies. For instance, what controls
the FOXP1-FOXP1-ES splicing switch?
What splicing factors are responsible for
flipping this switch, and how are their
expression and activities regulated? An-
swering these questions is like hunting
down the ‘‘chicken-or-the egg’’ paradox,
but they will ultimately uncover themaster
regulator of stem cell pluripotency.REFERENCES
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Although genes associated with human autism spectrum disorders have been identified, bridging
the gap between genetics and the patchwork of behavioral deficits associated with the disease
remains an enormous challenge. Pen˜agarikano et al. (2011) now show that mice lacking CNTNAP2,
a gene that causes a rare form of epilepsy associated with autistic features and language impair-
ment, display similar phenotypes to their human counterparts, raising hopes that such models
may speed the identification of neuronal circuitries underlying the core features of autism.Disorders that affect behavior, including
both psychiatric conditions and develop-
mental disabilities, provide challenging
opportunities and pitfalls for neuroscien-
tists. In autism, a three-domain model de-
scribing deficits in communication, social
interaction, and fixated or repetitive be-
haviors and interests has proven useful
as a ‘‘grammar’’ to represent the nature
of the deficits and to yield reliable diag-
noses (Figure 1A). This model does not,
however, necessarily reflect functional
relationships between behaviors (Gotham
et al., 2007). Such limitations underlie
both the strengths and weaknesses of
bold, integrative approaches such as
those found in this issue in Pen˜agarikano
et al. (2011), which reports a comprehen-
sive and ambitious series of experimental
behavioral, neuropathological, and neu-
rophysiological studies of CNTNAP2
knockout mice.
CNTNAP2, a gene on chromosome
7q35, is of particular interest because it
has been shown to cause a rare form of
epilepsy (Strauss et al., 2006). These
patients have severe intellectual disabilities
and, like most individuals with severe
cognitive deficits, are described as havingfeatures of autism. Although it likely ac-
counts for fewer than 1% of cases of
autism spectrum disorder (ASD) (Sanders
etal., 2011),CNTNAP2hasalsobeenasso-
ciated with specific language impairment
(SLI), which is characterized by difficulties
with grammatical aspects of language ac-
quisition in the absence of related causes
such as hearing loss (Bishop, 2010).
CNTNAP2 is also a downstream target of
FOXP2, one of the first genes to have
been identified as a cause of SLI.
In common with some human
CNTNAP2 patients, CNTNAP2 mutant
mice have epileptic seizures and display
impaired migration of cortical projection
neurons, cortical neuronal synchrony,
and numbers of GABAergic interneurons.
To quantify the behavioral impact of these
anatomical and electrophysiological de-
fects, the authors assess knockout and
wild-type mice for behaviors considered
analogous to the three domains of autism.
Standards for interpreting behavioral data
in mouse models have become more so-
phisticated (Silverman et al., 2010). How-
ever, leaps made from findings to inter-
pretations are still often substantial
(Minshew and McFadden, 2011). Pen˜a-garikano et al. (2011) report multiple mea-
sures and address several confounding
factors such as potential olfactory impair-
ment and the effect of sedation. Most
striking, though not obviously anticipated,
is that the mutant mice have deficits
across diverse contexts and domains. On
average, mice lacking CNTNAP2 make
fewer social approaches and engage in
less vocalization and nesting. In contrast,
perseveration, grooming, and digging
(used to indicate repetitive behaviors) are
enhanced, as are overall levels of activity.
Treatment with risperidone, an atypical
antipsychotic drug licensed for the treat-
ment of autism, increases nesting and
decreases grooming, perseveration, and
hyperactivity. However, risperidone has
no effect on social approach or vocaliza-
tion. The authors propose that these
specific responses to pharmacological
intervention are likely a result of the be-
haviors being driven by distinct neural
circuits. Though the idea that social defi-
cits and repetitive behaviors in autism
are separable on an anatomical level is
appealing, the absence of any attempt
to address functional relationships be-
tween these deficits within individuals in
